Join our community of traders FOR FREE!

  • Learn
  • Improve yourself
  • Get Rewards
Learn More

AUD/USD, a liquid proxy for risk, traded near a fresh 34-week low on Tuesday, as rising concerns about the impact of the Delta variant on global economic recovery triggered a rush to safety, supporting the US Dollar and the Japanese Yen.

“Learning to live with COVID is not being enthusiastically embraced amid the spread of the Delta variant,” Australia and New Zealand Banking Group strategists wrote in an investor note.

Since major macro data releases are absent this week, they expect both the Aussie and the kiwi dollars to be driven mostly by risk appetite.

Meanwhile, the Minutes from the Reserve Bank of Australia’s July policy meeting, released earlier on Tuesday, showed that Australia’s economic recovery had been stronger than earlier anticipated and that it was expected to continue.

“The effect of the recent virus outbreaks and the lockdowns had created additional uncertainty, but the experience to date had been that the economy bounced back quickly once outbreaks were contained and restrictions eased,” the Minutes stated.

The RBA reiterated that an interest rate hike would not occur until at least 2024.

The yield on the 10-year Australian government bonds went down 6 basis points to 1.172%, a level last seen in February.

As of 8:33 GMT on Tuesday AUD/USD was edging down 0.23% to trade at 0.7325, after earlier touching an intraday low at 0.7311. The latter has been the Forex pair’s weakest level since November 24th 2020 (0.7283). The major currency pair has retreated 2.30% so far in July, following another 2.99% drop in June.

Bond Yield Spread

The spread between 2-year Australian and 2-year US bond yields, which reflects the flow of funds in a short term, equaled -16.97 basis points (-0.1697%) as of 8:15 GMT on Tuesday, up from -18.7 basis points on July 19th.

Daily Pivot Levels (traditional method of calculation)

Central Pivot – 0.7355
R1 – 0.7389
R2 – 0.7436
R3 – 0.7470
R4 – 0.7504

S1 – 0.7308
S2 – 0.7275
S3 – 0.7228
S4 – 0.7181

TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover Forex, Price Action and Social Trading.

Related News

  • Sky share price up, reports strong first-half results on UK and Ireland growthSky share price up, reports strong first-half results on UK and Ireland growth Sky Plc reported on Wednesday an increase in earnings as the European pay-television operator benefited from a record customer growth in its UK and Irish operations.Rupert Murdoch-controlled Sky said adjusted revenue climbed to £5.6 […]
  • 3M Lifts Profit Forecast as Core Unit Outperforms3M Lifts Profit Forecast as Core Unit Outperforms Key Moments 3M shares climbed 6% in premarket trading after the company increased its full-year adjusted earnings forecast. The safety and industrial segment delivered more than 8% year-over-year quarterly sales growth, […]
  • Soft futures mixedSoft futures mixed Soft futures were mixed on Wednesday on the ICE Futures U.S. Exchange. Sugar prices bounced off lowest levels since July 2010 as investors returned to the market amid speculations prices will start climbing. Arabica coffee also rose, while […]
  • Gold retreats on Fed stimulus outlookGold retreats on Fed stimulus outlook Gold fell for the first time in six days as a stronger greenback pushed dollar-denominated commodities down amid expectations that Thursdays U.S. data will back the case that the Federal Reserve will begin tapering its monetary easing program […]
  • Forex Market: EUR/AUD daily forecastForex Market: EUR/AUD daily forecast During yesterday’s trading session EUR/AUD traded within the range of 1.4356-1.4426 and closed at 1.4364, losing 0.4% for the day.At 6:54 GMT today EUR/AUD was gaining 0.03% for the day to trade at 1.4368. The pair touched a daily high at […]
  • Pfizer Inc.’s share price down, to buy rights to a cancer drug of Merck at the price of $850 millionPfizer Inc.’s share price down, to buy rights to a cancer drug of Merck at the price of $850 million Pfizer Inc. is to pay $850 million for rights to a cancer drug, developed by Merck KGaA. The deal is to grant Pfizer the opportunity to get an experimental treatment such as the one it looked for when it made its takeover bid for Astrazeneca […]